Document is current
Any future updates will be listed below
-
Authors
Yu, Fulong
Cato, Liam D.
Weng, Chen
Liggett, L. Alexander
Jeon, Soyoung
Xu, Keren
Chiang, Charleston W. K. https://orcid.org/0000-0002-0668-7865
Wiemels, Joseph L. https://orcid.org/0000-0003-4838-9951
Weissman, Jonathan S. https://orcid.org/0000-0003-2445-670X
de Smith, Adam J.
Sankaran, Vijay G. https://orcid.org/0000-0003-0044-443X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32 HL007574, R01 HL146500)
Howard Hughes Medical Institute
New York Stem Cell Foundation
- License Information
-
More Information
Article History
Received: 20 January 2022
Accepted: 29 April 2022
First Online: 6 June 2022
Competing interests
: J.S.W. serves as an advisor to and/or has equity in KSQ Therapeutics, Maze Therapeutics and 5AM Ventures, all unrelated to the present work. V.G.S. serves as an advisor to and/or has equity in Branch Biosciences, Ensoma, Novartis, Forma and Cellarity, all unrelated to the present work. The authors have no other competing interests to declare.
